<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39340044</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>05</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Assessing the Impact of Primary-Series Infection and Booster Vaccination on Protection against Omicron in Hong Kong: A Population-Based Observational Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1014</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12091014</ELocationID><Abstract><AbstractText>This study aimed to assess the real-world effectiveness of vaccines and hybrid immunity in preventing infections during the Omicron prevalent period in Hong Kong. This study analyzed vaccination records and COVID-19 confirmed case records from 1 January 2022 to 28 January 2023 and included a total of 7,165,862 individuals with vaccination or infection records. This study found that an additional vaccine dose offered increased protection against Omicron BA.1/2 and BA.4 infections for individuals without prior infections in general. Hybrid immunity, acquired through vaccination and natural infection, was found to be significantly stronger than that provided by vaccines alone. The Comirnaty Original/Omicron BA.4/5 bivalent vaccine, introduced in December 2022, was associated with a lower risk of BA.4 infection when administered as a booster dose after three doses of CoronaVac. However, individuals with four doses of the CoronaVac vaccine did not exhibit a significantly lower risk of infection compared to those with three doses during the BA.4 dominant period. This study highlights the importance of promoting booster shot uptake and encouraging vaccination among those who have recovered from COVID-19 infections. The potential immune imprinting effect associated with the Comirnaty and CoronaVac vaccine underscores the need for continued surveillance and research to optimize vaccination strategies for emerging variants.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Jialiang</ForeName><Initials>J</Initials><Identifier Source="ORCID">0009-0009-0956-7832</Identifier><AffiliationInfo><Affiliation>Department of Statistics and Actuarial Science, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lau</LastName><ForeName>Eric Ho Yin</ForeName><Initials>EHY</Initials><Identifier Source="ORCID">0000-0002-6688-9637</Identifier><AffiliationInfo><Affiliation>Laboratory of Data Discovery for Health (D24H), Hong Kong Science and Technology Park, New Territories, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Ziyi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Statistics and Actuarial Science, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Guosheng</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Statistics and Actuarial Science, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Yun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Laboratory of Data Discovery for Health (D24H), Hong Kong Science and Technology Park, New Territories, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cowling</LastName><ForeName>Benjamin John</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Laboratory of Data Discovery for Health (D24H), Hong Kong Science and Technology Park, New Territories, Hong Kong SAR, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lam</LastName><ForeName>Kwok Fai</ForeName><Initials>KF</Initials><Identifier Source="ORCID">0000-0001-5453-994X</Identifier><AffiliationInfo><Affiliation>Department of Statistics and Actuarial Science, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Quantitative Medicine, Duke-NUS Medical School, Singapore 169857, Singapore.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CID-HKU2-12</GrantID><Agency>The Health and Medical Research Fund of the Health Bureau, Government of the Hong Kong Special Administrative Region, China</Agency><Country /></Grant><Grant><GrantID>T11-705/21-N</GrantID><Agency>The Research Grants Council of the Hong Kong Special Administrative Region, China</Agency><Country /></Grant><Grant><GrantID>HKU SRFS2021-7S03</GrantID><Agency>BJC is supported by an RGC Senior Research Fellowship from the University Grants Committee of Hong Kong</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Comirnaty</Keyword><Keyword MajorTopicYN="N">CoronaVac</Keyword><Keyword MajorTopicYN="N">Omicron</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>B.J.C. consults for AstraZeneca, Fosun Pharma, GlaxoSmithKline, Haleon, Moderna, Novavax, Pfizer, Roche, and Sanofi Pasteur. The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39340044</ArticleId><ArticleId IdType="pmc">PMC11435694</ArticleId><ArticleId IdType="doi">10.3390/vaccines12091014</ArticleId><ArticleId IdType="pii">vaccines12091014</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization  WHO Coronavirus (COVID-19) Dashboard.  [(accessed on 24 February 2024)].  Available online:  https://covid19.who.int/</Citation></Reference><Reference><Citation>Park S., Marcus G.M., Olgin J.E., Carton T., Hamad R., Pletcher M.J., Khatib R., Isasi C.R., Meissner P., Kitzman H., et al. Unreported SARS-CoV-2 Home Testing and Test Positivity. JAMA Netw. Open. 2023;6:e2252684. doi: 10.1001/jamanetworkopen.2022.52684.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.52684</ArticleId><ArticleId IdType="pmc">PMC10187483</ArticleId><ArticleId IdType="pubmed">36696115</ArticleId></ArticleIdList></Reference><Reference><Citation>Msemburi W., Karlinsky A., Knutson V., Aleshin-Guendel S., Chatterji S., Wakefield J. The WHO estimates of excess mortality associated with the COVID-19 pandemic. Nature. 2023;613:130–137. doi: 10.1038/s41586-022-05522-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05522-2</ArticleId><ArticleId IdType="pmc">PMC9812776</ArticleId><ArticleId IdType="pubmed">36517599</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami N., Hayden R., Hills T., Al-Samkari H., Casey J., Del Sorbo L., Lawler P.R., Sise M.E., Leaf D.E. Therapeutic advances in COVID-19. Nat. Rev. Nephrol. 2023;19:38–52. doi: 10.1038/s41581-022-00642-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41581-022-00642-4</ArticleId><ArticleId IdType="pmc">PMC9574806</ArticleId><ArticleId IdType="pubmed">36253508</ArticleId></ArticleIdList></Reference><Reference><Citation>Government Announces 2019 COVID-19 Vaccination Programme.  [(accessed on 24 February 2024)]; Available online:  https://www.info.gov.hk/gia/general/202102/18/P2021021800767.htm?fontSize=1.</Citation></Reference><Reference><Citation>COVID-19 Vaccination Programme.  [(accessed on 24 February 2024)]; Available online:  https://www.chp.gov.hk/en/features/106934.html.</Citation></Reference><Reference><Citation>The Government of the Hong Kong Special Administrative Region: SFH Authorises COVID-19 Vaccine by Fosun Pharma/BioNTech for Emergency Use in Hong Kong.  [(accessed on 24 February 2024)]; Available online:  https://www.info.gov.hk/gia/general/202101/25/P2021012500829.htm.</Citation></Reference><Reference><Citation>The Government of the Hong Kong Special Administrative Region: SFH Authorises COVID-19 Vaccine by Sinovac for Emergency use in Hong Kong.  [(accessed on 24 February 2024)]; Available online:  https://www.info.gov.hk/gia/general/202102/18/P2021021800495.htm.</Citation></Reference><Reference><Citation>Tanriover M.D., Doğanay H.L., Akova M., Güner H.R., Azap A., Akhan S., Köse Ş., Erdinç F.Ş., Akalın E.H., Tabak Ö.F., et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): Interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398:213–222. doi: 10.1016/S0140-6736(21)01429-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01429-X</ArticleId><ArticleId IdType="pmc">PMC8266301</ArticleId><ArticleId IdType="pubmed">34246358</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Zeng G., Pan H., Li C., Hu Y., Chu K., Han W., Chen Z., Tang R., Yin W., et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect. Dis. 2021;21:181–192. doi: 10.1016/S1473-3099(20)30843-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30843-4</ArticleId><ArticleId IdType="pmc">PMC7832443</ArticleId><ArticleId IdType="pubmed">33217362</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Pérez Marc G., Moreira E.D., Zerbini C., et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N. Engl. J. Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Roest S., Hoek R.A.S., Manintveld O.C. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N. Engl. J. Med. 2021;384:1968–1970. doi: 10.1056/nejmc2104281.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmc2104281</ArticleId><ArticleId IdType="pubmed">33882226</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung Y.Y.H., Lau E.H.Y., Yin G., Lin Y., Cowling B.J., Lam K.F. Effectiveness of Vaccines and Antiviral Drugs in Preventing Severe and Fatal COVID-19, Hong Kong. Emerg. Infect. Dis. 2024;30:70–78. doi: 10.3201/eid3001.230414.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid3001.230414</ArticleId><ArticleId IdType="pmc">PMC10756371</ArticleId><ArticleId IdType="pubmed">38040664</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung Y.Y.H., Lau E.H.Y., Yin G., Lin Y., Jiang J., Cowling B.J., Lam K.F., Cheung Y.Y.H., Lau E.H.Y., Yin G., et al. Joint analysis of vaccination effectiveness and antiviral drug effectiveness for COVID-19: A causal inference approach. Int. J. Infect. Dis. 2024;143:107012. doi: 10.1016/j.ijid.2024.107012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2024.107012</ArticleId><ArticleId IdType="pubmed">38521448</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsang N.N.Y., So H.C., Cowling B.J., Leung G.M., Ip D.K.M. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: A prospective cohort study. Lancet Infect. Dis. 2023;23:421–434. doi: 10.1016/S1473-3099(22)00732-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00732-0</ArticleId><ArticleId IdType="pmc">PMC9744442</ArticleId><ArticleId IdType="pubmed">36521506</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Raddad L.J., Chemaitelly H., Butt A.A. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. N. Engl. J. Med. 2021;385:187–189. doi: 10.1056/NEJMc2104974.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2104974</ArticleId><ArticleId IdType="pmc">PMC8117967</ArticleId><ArticleId IdType="pubmed">33951357</ArticleId></ArticleIdList></Reference><Reference><Citation>Collie S., Champion J., Moultrie H., Bekker L.-G., Gray G. Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa. N. Engl. J. Med. 2022;386:494–496. doi: 10.1056/NEJMc2119270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2119270</ArticleId><ArticleId IdType="pmc">PMC8757569</ArticleId><ArticleId IdType="pubmed">34965358</ArticleId></ArticleIdList></Reference><Reference><Citation>Israel A., Merzon E., A Schäffer A., Shenhar Y., Green I., Golan-Cohen A., Ruppin E., Magen E., Vinker S. Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: Test negative design study. BMJ. 2021;375:e067873. doi: 10.1136/bmj-2021-067873.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-067873</ArticleId><ArticleId IdType="pmc">PMC9083235</ArticleId><ArticleId IdType="pubmed">34819275</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg Y., Mandel M., Bar-On Y.M., Bodenheimer O., Freedman L., Haas E.J., Milo R., Alroy-Preis S., Ash N., Huppert A. Waning Immunity after the BNT162b2 Vaccine in Israel. N. Engl. J. Med. 2021;385:E85. doi: 10.1056/NEJMoa2114228.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2114228</ArticleId><ArticleId IdType="pmc">PMC8609604</ArticleId><ArticleId IdType="pubmed">34706170</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B., Lin Y., Xiong W., Liu C., Gao H., Ho F., Zhou J., Zhang R., Wong J.Y., Cheung J.K., et al. Comparison of control and transmission of COVID-19 across epidemic waves in Hong Kong: An observational study. Lancet Reg. Health West. Pac. 2024;43:100969. doi: 10.1016/j.lanwpc.2023.100969.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanwpc.2023.100969</ArticleId><ArticleId IdType="pmc">PMC10700518</ArticleId><ArticleId IdType="pubmed">38076326</ArticleId></ArticleIdList></Reference><Reference><Citation>Statistics on 5th Wave of COVID-19.  [(accessed on 24 February 2024)]; Available online:  https://www.coronavirus.gov.hk/pdf/5th_wave_statistics/5th_wave_statistics_20230129.pdf.</Citation></Reference><Reference><Citation>Wong S.-C., Au A.K.-W., Lo J.Y.-C., Ho P.-L., Hung I.F.-N., To K.K.-W., Yuen K.-Y., Cheng V.C.-C. Evolution and Control of COVID-19 Epidemic in Hong Kong. Viruses. 2022;14:2519. doi: 10.3390/v14112519.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14112519</ArticleId><ArticleId IdType="pmc">PMC9698160</ArticleId><ArticleId IdType="pubmed">36423128</ArticleId></ArticleIdList></Reference><Reference><Citation>Altarawneh H.N., Chemaitelly H., Ayoub H.H., Tang P., Hasan M.R., Yassine H.M., Al-Khatib H.A., Smatti M.K., Coyle P., Al-Kanaani Z., et al. Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. N. Engl. J. Med. 2022;387:21–34. doi: 10.1056/NEJMoa2203965.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2203965</ArticleId><ArticleId IdType="pmc">PMC9258753</ArticleId><ArticleId IdType="pubmed">35704396</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaitelly H., Ayoub H.H., Tang P., Coyle P.V., Yassine H.M., Al Thani A.A., Al-Khatib H.A., Hasan M.R., Al-Kanaani Z., Al-Kuwari E., et al. History of primary-series and booster vaccination and protection against Omicron reinfection. Sci. Adv. 2023;9:eadh0761. doi: 10.1126/sciadv.adh0761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.adh0761</ArticleId><ArticleId IdType="pmc">PMC10550237</ArticleId><ArticleId IdType="pubmed">37792951</ArticleId></ArticleIdList></Reference><Reference><Citation>Uversky V.N., Redwan E.M., Makis W., Rubio-Casillas A. IgG4 Antibodies Induced by Repeated Vaccination May Generate Immune Tolerance to the SARS-CoV-2 Spike Protein. Vaccines. 2023;11:991. doi: 10.3390/vaccines11050991.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11050991</ArticleId><ArticleId IdType="pmc">PMC10222767</ArticleId><ArticleId IdType="pubmed">37243095</ArticleId></ArticleIdList></Reference><Reference><Citation>Altarawneh H.N., Chemaitelly H., Ayoub H.H., Tang P., Hasan M.R., Yassine H.M., Al-Khatib H.A., Al Thani A.A., Coyle P., Al-Kanaani Z., et al. Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: An observational study. eBioMedicine. 2023;95:104734. doi: 10.1016/j.ebiom.2023.104734.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2023.104734</ArticleId><ArticleId IdType="pmc">PMC10404859</ArticleId><ArticleId IdType="pubmed">37515986</ArticleId></ArticleIdList></Reference><Reference><Citation>Monge S., Pastor-Barriuso R., A Hernán M. The imprinting effect of COVID-19 vaccines: An expected selection bias in observational studies. BMJ. 2023;381:e074404. doi: 10.1136/bmj-2022-074404.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-074404</ArticleId><ArticleId IdType="pubmed">37286211</ArticleId></ArticleIdList></Reference><Reference><Citation>CHP Investigates Locally Acquired SARS-CoV-2 Virus Cases with 1 032 Cases Tested Positive by Nucleic Acid Tests and 2 778 Cases by RATs As Well As 213 Imported Cases.  [(accessed on 24 February 2024)]; Available online:  https://www.info.gov.hk/gia/general/202209/30/P2022093000555.htm?fontSize=1.</Citation></Reference><Reference><Citation>Protect Oneself by Receiving Third Dose of COVID-19 Vaccine as Early as Possible.  [(accessed on 24 February 2024)]; Available online:  https://www.info.gov.hk/gia/general/202201/01/P2021123100506.htm?fontSize=1.</Citation></Reference><Reference><Citation>Bookings for Vaccination with BioNTech Bivalent Vaccine Opens to Eligible Persons Tomorrow.  [(accessed on 24 February 2024)]; Available online:  https://www.info.gov.hk/gia/general/202211/26/P2022112500453.htm?fontSize=1.</Citation></Reference><Reference><Citation>Xu J., Lam K.F., Chen F., Milligan P., Cheung Y.B. Semiparametric estimation of time-varying intervention effects using recurrent event data. Stat. Med. 2017;36:2682–2696. doi: 10.1002/sim.7319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.7319</ArticleId><ArticleId IdType="pubmed">28464565</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung Y.B., Ma X., Lam K.F., Yung C.F., Milligan P. Estimation of trajectory of protective efficacy in infectious disease prevention trials using recurrent event times. Stat. Med. 2024;43:1759–1773. doi: 10.1002/sim.10049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.10049</ArticleId><ArticleId IdType="pubmed">38396234</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox D.R. Regression Models and Life-Tables. J. R. Stat. Soc. Ser. B. 1972;34:187–202. doi: 10.1111/j.2517-6161.1972.tb00899.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.2517-6161.1972.tb00899.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao B., He L., Bao Y., Chen Y., Lu G., Zhang Y., Xu Y., Su B., Xu J., Wang Y., et al. Repeated vaccination of inactivated SARS-CoV-2 vaccine dampens neutralizing antibodies against Omicron variants in breakthrough infection. Cell Res. 2023;33:258–261. doi: 10.1038/s41422-023-00781-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-023-00781-8</ArticleId><ArticleId IdType="pmc">PMC9875169</ArticleId><ArticleId IdType="pubmed">36697703</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., Munro A.P., Feng S., Janani L., Aley P.K., Babbage G., Baxter D., Bula M., Cathie K., Chatterjee K., et al. Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial. J. Infect. 2023;86:540–541. doi: 10.1016/j.jinf.2023.03.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2023.03.025</ArticleId><ArticleId IdType="pmc">PMC10089831</ArticleId><ArticleId IdType="pubmed">37055303</ArticleId></ArticleIdList></Reference><Reference><Citation>Altarawneh H.N., Chemaitelly H., Hasan M.R., Ayoub H.H., Qassim S., AlMukdad S., Coyle P., Yassine H.M., Al-Khatib H.A., Benslimane F.M., et al. Protection against the Omicron Variant from Previous SARS-CoV-2 Infection. N. Engl. J. Med. 2022;386:1288–1290. doi: 10.1056/NEJMc2200133.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2200133</ArticleId><ArticleId IdType="pmc">PMC8849180</ArticleId><ArticleId IdType="pubmed">35139269</ArticleId></ArticleIdList></Reference><Reference><Citation>Japan’s Weekly COVID-19 Cases Rise for 10th Straight Week.  [(accessed on 31 July 2024)].  Available online:  https://english.kyodonews.net/news/2024/07/14a84c28e80c-japans-weekly-covid-19-cases-rise-for-10th-straight-week.html.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>